Related Experiment Video
Updated: Jun 8, 2026

06:19
Intracameral Injection in Rats with Low Risk of Adverse Effects
Published on: May 31, 2024
New injection recommendations for patients with diabetes.
1Endocrinologist, Clinic of Endocrinology, Skåne University Hospital, Malmö, Sweden.
Diabetes & Metabolism
|October 12, 2010
Summary
Proper injection technique is crucial for diabetes management, preventing complications like lipohypertrophy. New evidence-based guidelines offer practical advice for safe and effective self-injections.
Area of Science:
- Endocrinology
- Diabetes Management
- Injection Therapy
Background:
- Self-administered injections are fundamental in diabetes care.
- Optimal technique prevents intramuscular delivery and complications like lipohypertrophy.
- A lack of comprehensive, evidence-based guidelines for injection best practices exists.
Purpose of the Study:
- To develop and propose new, evidence-based guidelines for diabetes injection techniques.
- To consolidate expert knowledge into practical recommendations for patients and healthcare providers.
- To address the need for formal guidance on best practices in insulin and GLP-1 analog administration.
Main Methods:
- A systematic literature review of peer-reviewed studies on diabetes injections was performed.
- An international expert panel convened over two years to draft recommendations.
- The draft guidelines were reviewed and revised by 127 experts from 27 countries at the TITAN workshop.
Main Results:
- 157 out of 292 reviewed articles were relevant to the recommendations.
- Recommendations were graded for clinical practice weight and evidence support.
- Topics covered include technique, device use, insulin types, site care, and complication management.
Conclusions:
- The developed recommendations provide essential practical guidance for diabetes injection management.
- Adherence to these guidelines aims to improve injection comfort and efficacy.
- The guidelines are expected to reduce the incidence of injection-related complications.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Short-acting insulins are divided into rapid-acting...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
